## Andrea Viale

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9253751/publications.pdf Version: 2024-02-01



ANDREA VIALE

#	Article	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
2	Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism. Cell, 2012, 149, 656-670.	13.5	1,587
3	Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature, 2014, 514, 628-632.	13.7	998
4	Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer. Cell, 2014, 158, 185-197.	13.5	553
5	Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature, 2009, 457, 51-56.	13.7	289
6	Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Nature, 2017, 542, 119-123.	13.7	209
7	Tumors and Mitochondrial Respiration: A Neglected Connection. Cancer Research, 2015, 75, 3687-3691.	0.4	204
8	Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Nature, 2019, 568, 410-414.	13.7	129
9	DNA damage in stem cells activates p21, inhibits p53, and induces symmetric self-renewing divisions. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3931-3936.	3.3	123
10	InÂVivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Cell Reports, 2016, 16, 133-147.	2.9	114
11	Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature, 2017, 542, 362-366.	13.7	105
12	Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. Science, 2021, 373, eabj0486.	6.0	99
13	Telomere Dysfunction Drives Aberrant Hematopoietic Differentiation and Myelodysplastic Syndrome. Cancer Cell, 2015, 27, 644-657.	7.7	85
14	Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice. Blood, 2002, 100, 4391-4400.	0.6	84
15	Pre-existing Functional Heterogeneity of Tumorigenic Compartment as the Origin of Chemoresistance in Pancreatic Tumors. Cell Reports, 2019, 26, 1518-1532.e9.	2.9	70
16	Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer. Cancer Research, 2015, 75, 1091-1101.	0.4	68
17	p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell, 2019, 35, 204-220.e9.	7.7	62
18	Metabolic Features of Cancer Treatment Resistance. Recent Results in Cancer Research, 2016, 207, 135-156.	1.8	34

ANDREA VIALE

#	Article	IF	CITATIONS
19	PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. Nature Communications, 2021, 12, 4626.	5.8	31
20	The Many Facets of Tumor Heterogeneity: Is Metabolism Lagging Behind?. Cancers, 2019, 11, 1574.	1.7	28
21	Medium-Chain Acyl-CoA Dehydrogenase Protects Mitochondria from Lipid Peroxidation in Glioblastoma. Cancer Discovery, 2021, 11, 2904-2923.	7.7	23
22	Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. Gastroenterology, 2021, 161, 196-210.	0.6	23
23	Loss of ARID1A Promotes Epithelial–Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress. Cancer Research, 2021, 81, 332-343.	0.4	22
24	miRâ $\in 9$ modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC. EMBO Molecular Medicine, 2021, 13, e12872.	3.3	15
25	Leukotrienes, a potential target for Covid-19. Prostaglandins Leukotrienes and Essential Fatty Acids, 2020, 161, 102174.	1.0	12
26	Sugar? No Thank You, Just a Deep Breath of Oxygen for Cancer Stem Cells. Cell Metabolism, 2015, 22, 543-545.	7.2	9